Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 185 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Osteoporosis Postmenopausal Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Calorie Restriction With Leucine Supplementation

NCT01757340
View directory record Official record
Conditions
Obesity, Menopause, Osteoporosis, Sarcopenia
Interventions
Weight loss with normal protein and leucine intake, Weight loss with protein/leucine supplementation
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 4, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional Results available

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

NCT04964388
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
Interventions
GLP-1 receptor agonist
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
55 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Results available

A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide

NCT00557310
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
teriparatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Tucson, Arizona • Lakewood, Colorado • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

NCT01657162
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Lakewood, Colorado • Hialeah, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Results available

Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

NCT02589600
View directory record Official record
Conditions
Osteoporotic Fractures, Osteoporosis, Postmenopausal
Interventions
Zoledronic acid, vitamin D, calcium, Saline
Drug · Dietary Supplement · Other
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older · Female only
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New Kensington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional

Long Term Effects of Raloxifene Treatment on Bone Quality

NCT00532428
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
Raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Indianapolis, Indiana • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density

NCT00114270
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
letrozole, zoledronic acid
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Therapeutic Touch for Wrist Fractures in Postmenopausal Women

NCT00079521
View directory record Official record
Conditions
Osteoporosis, Fractures
Interventions
Therapeutic Touch
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
40 Years to 85 Years · Female only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 16, 2006 · Synced Sep 4, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional Results available

The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass

NCT01928082
View directory record Official record
Conditions
Hypercalciuria, Hypercalciuria, Familial Idiopathic, Osteopenia, Osteoporosis
Interventions
Transdermal estradiol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

NCT01575834
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Romosozumab, Placebo, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
7,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Tucson, Arizona • Laguna Hills, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Potassium Citrate on Bone Metabolism

NCT00357331
View directory record Official record
Conditions
Bone Diseases, Metabolic, Osteoporosis, Postmenopausal
Interventions
potassium citrate
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia

NCT02604836
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
1,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
142
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Results available

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

NCT02598934
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
50
States / cities
Montgomery, Alabama • Chandler, Arizona • Peoria, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Green Tea and Tai Chi for Bone Health

NCT00625391
View directory record Official record
Conditions
Osteoporosis
Interventions
Placebo, Green Tea Polyphenols (GTP), Placebo+Tai Chi (TC), GTP+TC
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
Female only
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)

NCT00303485
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Placebo, Vitamin D and calcium supplementation, ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
65 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Beverly Hills, California • La Jolla, California • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 4, 2026, 2:50 AM EDT
Active, not recruiting Phase 2 Interventional

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

NCT06577935
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
AGA2118, Placebo
Drug · Other
Lead sponsor
Angitia Biopharmaceuticals
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Gainesville, Georgia • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Results available

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

NCT00485953
View directory record Official record
Conditions
Bone Loss, Osteoporosis, Breast Cancer
Interventions
risedronate
Drug
Lead sponsor
Susan L. Greenspan
Other
Eligibility
55 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis

NCT01292187
View directory record Official record
Conditions
Osteopenia
Interventions
Oral calcitonin at dinnertime, Oral placebo at dinnertime, Oral calcitonin at bedtime, Oral placebo at bedtime
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Walnut Creek, California • Clearwater, Florida • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Not applicable Interventional

Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer

NCT00587925
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
Bone Mineral Density
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2009 · Synced Sep 4, 2026, 2:50 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

NCT02337387
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Blosozumab, Placebo
Biological · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

NCT03432533
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Not applicable Interventional

The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)

NCT00118508
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate (including placebo)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

NCT00035256
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
teriparatide, raloxifene HCl, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Maywood, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 14, 2007 · Synced Sep 4, 2026, 2:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women

NCT01250145
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
LY333334, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Female only
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Sep 4, 2026, 2:50 AM EDT